CALHM1 ion channel elicits amyloid-β clearance by insulin-degrading enzyme in cell lines and in vivo in the mouse brain

Journal of Cell Science

Volumn 128, Issue 13, 2015, Pages 2330-2338

  Vingtdeux, Valérie ^a,b,c,d,e   Chandakkar, Pallavi ^a,b   Zhao, Haitian ^a,b   Blanc, Lionel ^b   Ruiz, Santiago ^a,b   Marambaud, Philippe ^a,b  

^a Litwin Zucker Research Center for the Study of Alzheimer's Disease and Memory Disorders   (United States)

^b FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^c JEAN PIERRE AUBERT RESEARCH CENTER   (France)

^d UNIV LILLE   (France)

^e LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Alzheimer's disease; Amyloid peptide; CALHM1; Insulindegrading enzyme; Ion channel; Secretion

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; CALCIUM CHANNEL; CALCIUM HOMEOSTASIS MODULATOR 1; INSULIN; INSULINASE; UNCLASSIFIED DRUG; AICDA (ACTIVATION-INDUCED CYTIDINE DEAMINASE); AMYLOID BETA PROTEIN; CALCIUM; CALHM1 PROTEIN, HUMAN; CALHM1 PROTEIN, MOUSE; CYTIDINE DEAMINASE; MEMBRANE PROTEIN;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CALCIUM CELL LEVEL; CELL FRACTIONATION; CELL MIGRATION; CELLULAR DISTRIBUTION; CHANNEL GATING; CLEARANCE; CONTROLLED STUDY; DOWN REGULATION; ELECTRIC ACTIVITY; EMBRYO; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INSULIN DEGRADATION; ION PERMEABILITY; ION TRANSPORT; MOUSE; NONHUMAN; PERMEABILITY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; PROTEIN STABILITY; PROTEIN TRANSPORT; SECRETORY PATHWAY; STEADY STATE; UPREGULATION; ANIMAL; BRAIN; CELL LINE; DEFICIENCY; DRUG EFFECTS; EXTRACELLULAR SPACE; KNOCKOUT MOUSE; METABOLISM; SOLUBILITY;

MUS;

AMYLOID BETA-PEPTIDES; ANIMALS; BRAIN; CALCIUM; CALCIUM CHANNELS; CELL LINE; CYTIDINE DEAMINASE; EXTRACELLULAR SPACE; HUMANS; INSULYSIN; MEMBRANE GLYCOPROTEINS; MICE, KNOCKOUT; PROTEOLYSIS; SOLUBILITY;

EID: 84935496189     PISSN: 00219533     EISSN: 14779137     Source Type: Journal    
DOI: 10.1242/jcs.167270     Document Type: Article

References (43)

1. Aguilar, D., Skrabanek, L., Gross, S. S., Oliva, B. and Campagne, F. (2008). Beyond tissueInfo: functional prediction using tissue expression profile similarity searches. Nucleic Acids Res. 36, 3728-3737.
2. Benilova, I., Gallardo, R., Ungureanu, A.-A., Castillo Cano, V., Snellinx, A., Ramakers, M., Bartic, C., Rousseau, F., Schymkowitz, J. and De Strooper, B. (2014). The Alzheimer disease protective mutation A2T modulates kinetic and thermodynamic properties of amyloid-β (Aβ) aggregation. J. Biol. Chem. 289, 30977-30989.
3. Berridge, M. J. (2010). Calcium hypothesis of Alzheimer's disease. Pflugers Arch. Eur. J. Physiol. 459, 441-449.
4. Chapuis, J., Vingtdeux, V., Campagne, F., Davies, P. and Marambaud, P. (2011). Growth arrest-specific 1 binds to and controls the maturation and processing of the amyloid-beta precursor protein. Hum. Mol. Genet. 20, 2026-2036.
5. Citron, M. (2010). Alzheimer's disease: strategies for disease modification. Nat. Rev. Drug Discov. 9, 387-398.
6. Clare, J. J. (2010). Targeting ion channels for drug discovery. Discov. Med. 9, 253-260.
7. de Leon, M. J., Mosconi, L., Blennow, K., Desanti, S., Zinkowski, R., Mehta, P. D., Pratico, D., Tsui, W., Saint Louis, L. A., Sobanska, L. et al. (2007). Imaging and CSF studies in the preclinical diagnosis of Alzheimer's disease. Ann. N. Y. Acad. Sci. 1097, 114-145.
8. De Strooper, B., Vassar, R. and Golde, T. (2010). The secretases: enzymes with therapeutic potential in Alzheimer disease. Nat. Rev. Neurol. 6, 99-107.
9. Dreses-Werringloer, U., Lambert, J.-C., Vingtdeux, V., Zhao, H., Vais, H., Siebert, A., Jain, A., Koppel, J., Rovelet-Lecrux, A., Hannequin, D. et al. (2008). A polymorphism in CALHM1 influences Ca2+ homeostasis, Abeta levels, and Alzheimer's disease risk. Cell 133, 1149-1161.
10. Dreses-Werringloer, U., Vingtdeux, V., Zhao, H., Chandakkar, P., Davies, P. and Marambaud, P. (2013). CALHM1 controls the Ca2+-dependent MEK, ERK, RSK and MSK signaling cascade in neurons. J. Cell Sci. 126, 1199-1206.
11. Duyckaerts, C., Delatour, B. and Potier, M.-C. (2009). Classification and basic pathology of Alzheimer disease. Acta Neuropathol. 118, 5-36.
12. Edbauer, D., Willem, M., Lammich, S., Steiner, H. and Haass, C. (2002). Insulin-degrading enzyme rapidly removes the beta-amyloid precursor protein intracellular domain (AICD). J. Biol. Chem. 277, 13389-13393.
13. Espuny-Camacho, I., Dominguez, D., Merchiers, P., Van Rompaey, L., Selkoe, D. and De Strooper, B. (2010). Peroxisome proliferator-activated receptor gamma enhances the activity of an insulin degrading enzyme-like metalloprotease for amyloid-beta clearance. J. Alzheimers Dis. 20, 1119-1132.
14. Farris,W., Mansourian, S., Chang, Y., Lindsley, L., Eckman, E. A., Frosch, M. P., Eckman, C. B., Tanzi, R. E., Selkoe, D. J. and Guenette, S. (2003). Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc. Natl. Acad. Sci. USA 100, 4162-4167.
15. Giedraitis, V., Glaser, A., Sarajärvi, T., Brundin, R., Gunnarsson, M. D., Schjeide, B.-M., Tanzi, R. E., Helisalmi, S., Pirttilä, T., Kilander, L. et al. (2010). CALHM1 P86L polymorphism does not alter amyloid-beta or tau in cerebrospinal fluid. Neurosci. Lett. 469, 265-267.
16. Haass, C. and Selkoe, D. J. (2007). Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat. Rev. Mol. Cell Biol. 8, 101-112.
17. Hardy, J. and Selkoe, D. J. (2002). The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353-356.
18. Jonsson, T., Atwal, J. K., Steinberg, S., Snaedal, J., Jonsson, P. V.,Bjornsson, S., Stefansson, H., Sulem, P., Gudbjartsson, D., Maloney, J. et al. (2012). A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature 488, 96-99.
19. Kauwe, J. S., Cruchaga, C., Bertelsen, S., Mayo, K., Latu, W., Nowotny, P., Hinrichs, A. L., Fagan, A. M., Holtzman, D. M., Goate, A. M. et al. (2010). Validating predicted biological effects of Alzheimer's disease associated SNPs using CSF biomarker levels. J. Alzheimers Dis. 21, 833-842.
20. Knops, J., Gandy, S., Greengard, P., Lieberburg, I. and Sinha, S. (1993). Serine phosphorylation of the secreted extracellular domain of APP. Biochem. Biophys. Res. Commun. 197, 380-385.
21. Koppel, J., Campagne, F., Vingtdeux, V., Dreses-Werringloer, U., Ewers, M., Rujescu, D., Hampel, H., Gordon, M. L., Christen, E., Chapuis, J. et al. (2011). CALHM1 P86L polymorphism modulates CSF Aβ levels in cognitively healthy individuals at risk for Alzheimer's disease. Mol. Med. 17, 974-979.
22. Lambert, J.-C. and Amouyel, P. (2011). Genetics of Alzheimer's disease: new evidences for an old hypothesis? Curr. Opin. Genet. Dev. 21, 295-301.
23. Lambert, J. C., Sleegers, K., González-Pérez, A., Ingelsson, M., Beecham, G. W., Hiltunen, M., Combarros, O., Bullido, M. J., Brouwers, N., Bettens, K. et al. (2010). The CALHM1 P86L polymorphism is a genetic modifier of age at onset in Alzheimer's disease: a meta-analysis study. J. Alzheimers Dis. 22, 247-255.
24. Langhans, M., Hawes, C., Hillmer, S., Hummel, E. and Robinson, D. G. (2007). Golgi regeneration after brefeldin A treatment in BY-2 cells entails stack enlargement and cisternal growth followed by division. Plant Physiol. 145, 527-538.
25. Leissring, M. A. and Turner, A. J. (2013). Regulation of distinct pools of amyloid β-protein by multiple cellular proteases. Alzheimers Res. Ther. 5, 37.
26. Lippincott-Schwartz, J., Yuan, L. C., Bonifacino, J. S. and Klausner, R. D. (1989). Rapid redistribution of Golgi proteins into the ER in cells treated with brefeldin A: evidence for membrane cycling from Golgi to ER. Cell 56, 801-813.
27. Ma, Z., Siebert, A. P., Cheung, K.-H., Lee, R. J., Johnson, B., Cohen, A. S., Vingtdeux, V., Marambaud, P. and Foskett, J. K. (2012). Calcium homeostasis modulator 1 (CALHM1) is the pore-forming subunit of an ion channel that mediates extracellular Ca2+ regulation of neuronal excitability. Proc. Natl. Acad. Sci. USA 109, E1963-E1971.
28. Maloney, J. A., Bainbridge, T., Gustafson, A., Zhang, S., Kyauk, R., Steiner, P., van der Brug, M., Liu, Y., Ernst, J. A., Watts, R. J. et al. (2014). Molecular mechanisms of Alzheimer disease protection by the A673T allele of amyloid precursor protein. J. Biol. Chem. 289, 30990-31000.
29. Marambaud, P. and Robakis, N. K. (2005). Genetic and molecular aspects of Alzheimer's disease shed light on new mechanisms of transcriptional regulation. Genes Brain Behav. 4, 134-146.
30. Marambaud, P., Wen, P. H., Dutt, A., Shioi, J., Takashima, A., Siman, R. and Robakis, N. K. (2003). A CBP binding transcriptional repressor produced by the PS1/epsilon-cleavage of N-cadherin is inhibited by PS1 FAD mutations. Cell 114, 635-645.
31. Miller, B. C., Eckman, E. A., Sambamurti, K., Dobbs, N., Chow, K. M., Eckman, C. B., Hersh, L. B. and Thiele, D. L. (2003). Amyloid-beta peptide levels in brain are inversely correlated with insulysin activity levels in vivo. Proc. Natl. Acad. Sci. USA 100, 6221-6226.
32. Nixon, R. A., Yang, D.-S. and Lee, J.-H. (2008). Neurodegenerative lysosomal disorders: a continuum from development to late age. Autophagy 4, 590-599.
33. Pflanzner, T., Kuhlmann, C. R. and Pietrzik, C. U. (2010). Blood-brain-barrier models for the investigation of transporter- and receptor-mediated amyloid-β clearance in Alzheimer's disease. Curr. Alzheimer Res. 7, 578-590.
34. Rusakov, D. A. and Fine, A. (2003). Extracellular Ca2+ depletion contributes to fast activity-dependent modulation of synaptic transmission in the brain. Neuron 37, 287-297.
35. Serrano-Pozo, A., Frosch, M. P., Masliah, E. and Hyman, B. T. (2011). Neuropathological alterations in Alzheimer disease. Cold Spring Harb. Perspect. Med. 1, a006189.
36. Siebert, A. P., Ma, Z., Grevet, J. D., Demuro, A., Parker, I. and Foskett, J. K. (2013). Structural and functional similarities of calcium homeostasis modulator 1 (CALHM1) ion channel with connexins, pannexins, and innexins. J. Biol. Chem. 288, 6140-6153.
37. Tanis, J. E., Ma, Z., Krajacic, P., He, L., Foskett, J. K. and Lamitina, T. (2013). CLHM-1 is a functionally conserved and conditionally toxic Ca2+-permeable ion channel in Caenorhabditis elegans. J. Neurosci. 33, 12275-12286.
38. Taruno,A., Vingtdeux, V.,Ohmoto,M.,Ma, Z.,Dvoryanchikov,G., Li,A., Adrien, L., Zhao, H., Leung, S., Abernethy, M. et al. (2013). CALHM1 ion channel mediates purinergic neurotransmission of sweet, bitter and umami tastes. Nature 495, 223-226.
39. Turner, A. J. and Nalivaeva, N. N. (2007). New insights into the roles of metalloproteinases in neurodegeneration and neuroprotection. Int. Rev. Neurobiol. 82, 113-135.
40. Vekrellis, K., Ye, Z., Qiu, W. Q., Walsh, D., Hartley, D., Chesneau, V., Rosner, M. R. and Selkoe, D. J. (2000). Neurons regulate extracellular levels of amyloid beta-protein via proteolysis by insulin-degrading enzyme. J. Neurosci. 20, 1657-1665.
41. Vingtdeux, V., Giliberto, L., Zhao, H., Chandakkar, P., Wu, Q., Simon, J. E., Janle, E. M., Lobo, J., Ferruzzi, M. G., Davies, P. et al. (2010). AMP-activated protein kinase signaling activation by resveratrol modulates amyloid-beta peptide metabolism. J. Biol. Chem. 285, 9100-9113.
42. Vingtdeux, V., Tanis, J. E., Chandakkar, P., Zhao, H., Dreses-Werringloer, U., Campagne, F., Foskett, J. K. and Marambaud, P. (2014). Effect of the CALHM1 G330D and R154H Human Variants on the Control of Cytosolic Ca2+ and Aβ Levels. PLoS ONE 9, e112484.
43. Zolezzi, J. M., Bastías-Candia, S., Santos, M. J. and Inestrosa, N. C. (2014). Alzheimer's disease: relevant molecular and physiopathological events affecting amyloid-β brain balance and the putative role of PPARs. Front. Aging Neurosci. 6, 176.